Open AccessImatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
Author(s) -
F. Stephen Hodi,
Christopher L. Corless,
Anita GiobbieHurder,
Jonathan A. Fletcher,
Meijun Zhu,
Adrián MariñoEnríquez,
Philip Friedlander,
René González,
Jeffrey S. Weber,
Thomas F. Gajewski,
Steven O’Day,
Kevin B. Kim,
Donald P. Lawrence,
Keith T. Flaherty,
Jason J. Luke,
Frances A. Collichio,
Marc S. Ernstoff,
Michael C. Heinrich,
Carol Beadling,
Katherine Zukotynski,
Jeffrey T. Yap,
Annick D. Van den Abbeele,
George D. Demetri,
David E. Fisher
Publication year - 2013
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2012.47.7836
Subject(s) - neuroblastoma ras viral oncogene homolog , medicine , imatinib , melanoma , mutation , gastroenterology , oncology , cancer research , cancer , biology , gene , kras , genetics , colorectal cancer , myeloid leukemia
Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom